Incidence, Clinical Features, and Contributing Factors of Capecitabine-Related Hand–Foot Syndrome in Cancer Patients: Insights from Sudan - Summary - MDSpire
Advertisement
Incidence, Clinical Features, and Contributing Factors of Capecitabine-Related Hand–Foot Syndrome in Cancer Patients: Insights from Sudan
To determine the prevalence of capecitabine-induced hand-foot syndrome (HFS) and evaluate its clinical characteristics and associated factors among cancer patients receiving capecitabine in Sudan, highlighting its significance for local healthcare.
Key Findings:
More than half of the patients developed hand-foot syndrome (specific percentage needed).
Female patients and those undergoing multiple chemotherapy cycles were less likely to experience HFS (specific data needed).
Absence of concomitant diseases was associated with a higher likelihood of developing HFS (specific data needed).
Interpretation:
Early recognition and management of HFS can enhance quality of life and reduce treatment interruptions in cancer patients, emphasizing the need for tailored patient education.
Limitations:
Study limited to a single center, which may affect generalizability and introduce selection bias.
Exclusion of patients receiving combination therapies may limit understanding of HFS in broader contexts, suggesting a need for future studies.
Conclusion:
The study highlights the high incidence of capecitabine-related HFS in Sudanese cancer patients and underscores the importance of patient education and timely management, while calling for further research to explore broader implications.
